

The background of the cover features a 3D surface representation of a protein. The protein is shown in a light blue/gray color, with several distinct patches of red and orange, likely representing specific binding sites or functional regions. The protein is oriented vertically, with the larger part of the structure on the left side of the cover.

PROTEIN SURFACE RECOGNITION

APPROACHES FOR DRUG DISCOVERY

EDITORS

ERNEST GIRALT, MARK W. PECZUH
AND XAVIER SALVATELLA

 WILEY

Contents

<i>Preface</i>	<i>xi</i>
<i>List of Contributors</i>	<i>xv</i>
PART I Principles	1
1 The Discovery and Characterization of Protein–Protein Interactions	3
<i>C. W. Bertoncini, A. Higuero and X. Salvatella</i>	
1.1 Introduction	3
1.2 Techniques to Identify Protein–Protein Interactions	4
1.2.1 The Yeast Two Hybrid Assay (Y2H)	4
1.2.2 Phage Display	5
1.2.3 Protein Microarrays	6
1.2.4 Affinity-based Methods	7
1.2.5 FRET-based Detection of Protein–Protein Interactions	10
1.3 Techniques to Characterize Protein–Protein Interactions	11
1.3.1 X-ray Crystallography	11
1.3.2 Nuclear Magnetic Resonance (NMR)	12
1.3.3 Isothermal Titration Calorimetry (ITC)	12
1.3.4 Other Techniques	12
1.4 Structure and Dynamics of Protein Complexes	13
1.4.1 Functional Classification of Protein–Protein Complexes	13
1.4.2 Differentiation Between Crystallographic and Functional Complexes	13
1.4.3 Classification Based on the Nature of the Constituents and the Lifetime of the Complex	14
1.4.4 Descriptors and Topology of Protein Complexes	14
1.5 Protein–Protein Complexes as Therapeutic Targets	17
1.5.1 Challenging Undruggability	17
1.6 Conclusions	18
References	18
2 Biophysics of Protein–Protein Interactions	23
<i>Irene Luque</i>	
2.1 Introduction	23
2.2 Intermolecular Forces in Protein Recognition	24
2.3 Basic Binding Thermodynamics	26

2.4	Thermodynamically Driven Drug Design	28
2.4.1	Entropic Optimization of Lead Compounds	29
2.4.2	Guidelines for Enthalpic Optimization of Ligands	29
2.5	Measurement of Binding Energetics	31
2.5.1	Calorimetric vs Noncalorimetric Techniques	31
2.5.2	Principles of Isothermal Titration Calorimetry	33
2.5.3	The ITC Experiment	35
2.6	Structure-based Calculation of Protein Binding Energetics	37
2.7	Interfacial Water Molecules in Protein Recognition	38
2.8	The Linkage Between Binding and Conformational Equilibrium in Proteins	40
2.8.1	The Native State Ensemble	41
2.8.2	The Structural Stability of Binding Sites	42
2.8.3	Signal Transduction and Allostereism	44
	References	45
PART II Approaches		53
3	On the Logic of Natural Product Binding in Protein-Protein Interactivity	55
	<i>James J. La Clair</i>	
3.1	Introduction	55
3.2	Structural Logic	56
3.3	Functional Logic	61
3.4	The Need for Programmers	63
3.5	Compiling the NPPI Mapper	67
	References	67
4	Interface Peptides	75
	<i>Mark W. Pecuh and Richard T. Desmond</i>	
4.1	Interface Peptides Defined	75
4.2	Unmodified Peptides	77
4.2.1	Examples of Interface Peptides	78
4.2.2	Guiding Concepts	84
4.2.3	Folded Interface Peptides – Protein Grafting	85
4.3	Modified Peptides	88
4.3.1	Peptides Constrained to an α -Helical Conformation	88
4.3.2	Peptides Constrained to a β -Hairpin Conformation	90
4.3.3	β -Peptides as Interface Peptides: Foldamers	92
4.4	Summary/Perspective	94
	References	94

5	Inhibition of Protein–Protein Interactions by Peptide Mimics	105
	<i>Jorge Becerril, Johanna M. Rodriguez, Pauline N. Wyrembak and Andrew D. Hamilton</i>	
5.1	Introduction	105
5.2	Inhibition of Calmodulin	106
	5.2.1 Introduction	106
	5.2.2 Small-Molecule Inhibitors	106
5.3	Inhibition of HIV-1 Fusion	108
	5.3.1 Introduction	108
	5.3.2 Nonnatural Oligomers: β -peptides	109
	5.3.3 β -Turn Mimetics	110
	5.3.4 Small-Molecule Inhibitors	110
5.4	Inhibition of the Nuclear Estrogen Receptor	111
	5.4.1 Introduction	111
	5.4.2 Nonnatural Oligomers: Cyclic Peptides	112
	5.4.3 Small-Molecule Inhibitors	113
5.5	Inhibition of the Bcl- x_L /Bak Interaction	114
	5.5.1 Introduction	114
	5.5.2 Nonnatural Oligomers: β -peptides	115
	5.5.3 Small-Molecule Inhibitors	116
5.6	Inhibition of the p53/MDM2 Interaction	118
	5.6.1 Introduction	118
	5.6.2 Nonnatural Oligomers	118
	5.6.3 β -Hairpin Mimetics	119
5.7	Miscellaneous Protein Targets	121
	5.7.1 Inhibition of Neurotrophins	121
	5.7.2 Inhibition of the Grb2 SH2 Domain	122
	5.7.3 Inhibition of the Myd88/IL-1RI Interaction	123
	5.7.4 Inhibition of the ICAM-1/LFA-1 Interaction	124
	5.7.5 Inhibition of PDZ Domains	125
5.8	Conclusion	126
	References	126
6	Discovery of Inhibitors of Protein–Protein Interactions by Screening Chemical Libraries	133
	<i>Carlos García-Echeverría</i>	
6.1	Introduction	133
6.2	Screening Strategies to Identify and Develop Antagonists of Protein–Protein Interactions	134
	6.2.1 Phage Display Libraries, Peptides and Unnatural Biopolymers – Mapping Protein Surfaces	134
	6.2.2 Synthetic and Natural Modulators of Protein–Protein Interactions from High-throughput Data-Generation Techniques	135

6.2.3	Virtual Database Screening Strategies	139
6.2.4	Fragment Libraries – Screening for Weak Interactions	142
6.3	Mimetics of Common Protein Structure Motifs and Structure-based Design of Peptidomimetics	144
6.4	Conclusions and Outlook	149
	References	149
PART III Techniques		155
7	High-throughput Methods of Chemical Synthesis Applied to the Preparation of Inhibitors of Protein–Protein Interactions	157
	<i>Annaliese K. Franz, Jared T. Shaw and Yuchen Tang</i>	
7.1	Introduction	157
7.2	Survey of High-throughput Organic Synthesis	159
7.3	Synthesis of ‘Peptide-Inspired’ Compounds and Libraries	162
7.4	Synthesis of ‘Natural Product-Inspired’ Compounds and Libraries	174
7.5	Diversity Oriented Synthesis (DOS) in the Discovery of PPI Inhibitors	188
7.6	Summary and Outlook	200
	References	201
8	In Silico Screening	211
	<i>F.J. Luque and X. Barril</i>	
8.1	Introduction	211
8.2	Methods for Virtual Ligand Screening	212
	8.2.1 Chemoinformatics and Ligand-based Methods	212
	8.2.2 Structure-based Methods	214
8.3	Binding Site Characterization	219
	8.3.1 Hot Spots Analysis	219
	8.3.2 Cavity Druggability	222
	8.3.3 Binding Site Plasticity	224
8.4	Case Studies	225
	8.4.1 β -Catenin Inhibitors	226
	8.4.2 Small Molecule Modulators of $G\beta\gamma$ activity	227
8.5	Outlook and Conclusions	228
	References	229
9.1	In Vitro Screening: Screening by Nuclear Magnetic Resonance	237
	<i>Ernest Giralt</i>	
9.1.1	Saturation Transfer Difference (STD)	238
9.1.2	STD in Fragment-based Drug Design	241
9.1.3	Chemical Shift Perturbation (CSP)	242
9.1.4	^{19}F -NMR in Molecular Recognition Studies	246
	References	248

9.2 In Vitro Screening: Methods of High-throughput Screening	251
<i>Wenjiao Song and Qing Lin</i>	
9.2.1 Introduction	251
9.2.2 Statistical Evaluation of the HTS Assay Performance	252
9.2.3 Biochemical Assays	253
9.2.4 Cell-based Assays	264
9.2.5 Conclusion	269
References	270
PART IV Case Studies	273
10 Case Study: Inhibitors of the MDM2-p53 Protein-Protein Interaction	275
<i>Sanjeev Shangary, Deniz Bernard and Shaomeng Wang</i>	
10.1 MDM2-p53 Protein-Protein Interaction: A Case Study	275
10.2 Regulation of p53 by the MDM2-p53 Protein-Protein Interaction	277
10.3 Structural Basis of the MDM2-p53 Interaction	278
10.4 Design of p53-based Peptides	279
10.5 Design of Nonpeptidic Small-Molecule Inhibitors of the MDM2-p53 Interaction	279
10.5.1 Screening Chemical Databases	279
10.5.2 Computational Database Screening	287
10.5.3 Structure-based <i>de Novo</i> Design	288
10.6 Challenges in the Design of Small Molecule Inhibitors of the MDM2-p53 Interaction	289
10.6.1 Binding Affinity and Specificity	289
10.6.2 Solubility and Cell Permeability	289
10.6.3 <i>In Vivo</i> Pharmacological Properties	290
10.7 Reactivation of p53 by Inhibitors of the MDM2-p53 Interaction	290
10.8 Development of MDM2 Inhibitors as New Anticancer Drugs	290
10.9 Concluding Remarks	291
Acknowledgements	291
Disclosure Statement	292
References	292
11 Case Study: The Discovery of Potent LFA-1 Antagonists	295
<i>Tom Gadek</i>	
11.1 Introduction	295
11.2 Structural, Molecular and Cellular Biologies of LFA-1	296
11.3 The Search for Small Molecule LFA-1 Antagonists	300
11.4 Screening Assays	301

x *Contents*

11.5	Lead Identification and Optimization	304
11.5.1	Novartis	304
11.5.2	Boehringer Ingelheim	304
11.5.3	Abbott/ICOS	306
11.5.4	Bristol-Myers Squibb	306
11.5.5	Genentech	307
11.6	Protein and Small Molecule Structure Activity Relationships (PSAR) in the LFA-1/ICAM-1 Interaction	307
11.7	Summary	309
	References	310

Index

315